Short-term use of intravenous milrinone for heart failure.

[1]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[2]  F. Epstein,et al.  Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. , 1991, The New England journal of medicine.

[3]  W. Grossman.  Diastolic dysfunction and congestive heart failure. , 1990, Circulation.

[4]  J. Kostis,et al.  The use of inotropic agents in acute and chronic congestive heart failure. , 1989, The Medical clinics of North America.

[5]  W. Colucci.  Positive inotropic/vasodilator agents. , 1989, Cardiology clinics.

[6]  E. Sonnenblick,et al.  Effects of phosphodiesterase inhibition on skeletal muscle vasculature. , 1989, The American journal of cardiology.

[7]  R. Cody.  Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction. , 1988, Journal of the American College of Cardiology.

[8]  D. Faxon,et al.  Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. , 1987, The American journal of cardiology.

[9]  D. Baim,et al.  Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. , 1987, Journal of the American College of Cardiology.

[10]  S. Geraci,et al.  Electrophysiologic effects of milrinone in patients with congestive heart failure. , 1986, The American journal of cardiology.

[11]  T. LeJemtel,et al.  Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. , 1986, Journal of the American College of Cardiology.

[12]  J. Anderson,et al.  Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone. , 1986, American heart journal.

[13]  E. Braunwald,et al.  Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. , 1986, Circulation.

[14]  P. Kligfield,et al.  Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias. , 1985, American heart journal.

[15]  J. Alpert,et al.  Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. , 1985, The American journal of cardiology.

[16]  E. Braunwald,et al.  Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. , 1985, The Journal of clinical investigation.

[17]  D. Baim,et al.  Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. , 1984, Circulation.

[18]  R. Stroshane,et al.  Oral and intravenous pharmacokinetics of milrinone in human volunteers. , 1984, Journal of pharmaceutical sciences.

[19]  L. Horowitz,et al.  Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. , 1984, The American journal of cardiology.

[20]  V. Velebit,et al.  Aggravation and Provocation of Ventricular Arrhythmias by Antiarrhythmic Drugs , 1982, Circulation.

[21]  R. Ogilvie,et al.  A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure. , 1991, The Canadian journal of cardiology.

[22]  E. Braunwald,et al.  Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. , 1986, Circulation.

[23]  R. Cody,et al.  Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure. , 1986, Circulation.

[24]  D. Baim,et al.  Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. , 1986, Circulation.